134 related articles for article (PubMed ID: 37651827)
1. A CT-based novel model to predict pathological complete response of locally advanced esophageal squamous cell carcinoma to neoadjuvant PD-1 blockade in combination with chemotherapy.
Zhou HY; Guo WW; Ou J; Li R; Gui Y; Li L; Fu MY; Zhang XM; Chen TW
Eur J Radiol; 2023 Oct; 167():111065. PubMed ID: 37651827
[TBL] [Abstract][Full Text] [Related]
2. The role of
Wang X; Yang W; Zhou Q; Luo H; Chen W; Yeung SJ; Zhang S; Gan Y; Zeng B; Liu Z; Feng S; Zhang X; Cheng C
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4241-4251. PubMed ID: 35732974
[TBL] [Abstract][Full Text] [Related]
3. The MRI radiomics signature can predict the pathologic response to neoadjuvant chemotherapy in locally advanced esophageal squamous cell carcinoma.
Lu S; Wang C; Liu Y; Chu F; Jia Z; Zhang H; Wang Z; Lu Y; Wang S; Yang G; Qu J
Eur Radiol; 2024 Jan; 34(1):485-494. PubMed ID: 37540319
[TBL] [Abstract][Full Text] [Related]
4. CT-based radiomic signatures for prediction of pathologic complete response in esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy.
Yang Z; He B; Zhuang X; Gao X; Wang D; Li M; Lin Z; Luo R
J Radiat Res; 2019 Jul; 60(4):538-545. PubMed ID: 31111948
[TBL] [Abstract][Full Text] [Related]
5. Diffusion-weighted MRI and
Xu X; Sun ZY; Wu HW; Zhang CP; Hu B; Rong L; Chen HY; Xie HY; Wang YM; Lin HP; Bai YR; Ye Q; Ma XM
Radiat Oncol; 2021 Jul; 16(1):132. PubMed ID: 34281566
[TBL] [Abstract][Full Text] [Related]
6. Can lymphovascular invasion be predicted by contrast-enhanced CT imaging features in patients with esophageal squamous cell carcinoma? A preliminary retrospective study.
Li Y; Su H; Yang L; Yue M; Wang M; Gu X; Dai L; Wang X; Su X; Zhang A; Ren J; Shi G
BMC Med Imaging; 2022 May; 22(1):93. PubMed ID: 35581563
[TBL] [Abstract][Full Text] [Related]
7. The value of intravoxel incoherent motion diffusion-weighted imaging in predicting the pathologic response to neoadjuvant chemotherapy in locally advanced esophageal squamous cell carcinoma.
Song T; Yao Q; Qu J; Zhang H; Zhao Y; Qin J; Feng W; Zhang S; Han X; Wang S; Yan X; Li H
Eur Radiol; 2021 Mar; 31(3):1391-1400. PubMed ID: 32901300
[TBL] [Abstract][Full Text] [Related]
8. Impact of CT-assessed changes in tumor size after neoadjuvant chemotherapy on pathological response and survival of patients with esophageal squamous cell carcinoma.
Matsumoto S; Wakatsuki K; Nakade H; Kunishige T; Miyao S; Tsujimoto A; Tatsumi T; Sho M
Langenbecks Arch Surg; 2022 May; 407(3):965-974. PubMed ID: 34989856
[TBL] [Abstract][Full Text] [Related]
9. The safety and efficacy of neoadjuvant PD-1 inhibitor with chemotherapy for locally advanced esophageal squamous cell carcinoma.
Shen D; Chen Q; Wu J; Li J; Tao K; Jiang Y
J Gastrointest Oncol; 2021 Feb; 12(1):1-10. PubMed ID: 33708420
[TBL] [Abstract][Full Text] [Related]
10. Total Lesion Glycolysis Ratio in Positron Emission Tomography/Computed Tomography Images During Neoadjuvant Chemotherapy Can Predict Pathological Tumor Regression Grade and Prognosis in Patients with Locally Advanced Squamous Cell Carcinoma of the Esophagus.
Sonoda A; Yoshida N; Shiraishi S; Horinouchi T; Tokunaga R; Harada K; Iwatsuki M; Nagai Y; Baba Y; Iwagami S; Miyamoto Y; Baba H
Ann Surg Oncol; 2021 Jan; 28(1):167-174. PubMed ID: 32588261
[TBL] [Abstract][Full Text] [Related]
11. Response to neoadjuvant immune checkpoint inhibitors and chemotherapy in Chinese patients with esophageal squamous cell carcinoma: the role of tumor immune microenvironment.
Wang X; Ling X; Wang C; Zhang J; Yang Y; Jiang H; Xin Y; Zhang L; Liang H; Fang C; Zheng D; Zhu J; Ma J
Cancer Immunol Immunother; 2023 Jun; 72(6):1619-1631. PubMed ID: 36583750
[TBL] [Abstract][Full Text] [Related]
12. Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial : A randomized clinical trial of neoadjuvant therapy for ESCC.
Li Y; Zhou A; Liu S; He M; Chen K; Tian Z; Li Y; Qin J; Wang Z; Chen H; Tian H; Yu Y; Qu W; Xue L; He S; Wang S; Bie F; Bai G; Zhou B; Yang Z; Huang H; Fang Y; Li B; Dai X; Gao S; He J
BMC Med; 2023 Mar; 21(1):86. PubMed ID: 36882775
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of metabolic response to one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma.
Huang TC; Lin CC; Wu YC; Chia-Hsien Cheng J; Lee JM; Wang HP; Huang PM; Hsu FM; Yeh KH; Cheng AL; Tzen KY; Hsu CH
J Formos Med Assoc; 2019 Jun; 118(6):1024-1030. PubMed ID: 30502100
[TBL] [Abstract][Full Text] [Related]
14. Tumor Stage-Based Gross Tumor Volume of Resectable Esophageal Squamous Cell Carcinoma Measured on CT: Association With Early Recurrence After Esophagectomy.
Wu YP; Tang S; Tan BG; Yang LQ; Lu FL; Chen TW; Ou J; Zhang XM; Gao D; Li KY; Yu ZY; Tang Z
Front Oncol; 2021; 11():753797. PubMed ID: 34745986
[TBL] [Abstract][Full Text] [Related]
15.
Wang S; Di S; Lu J; Xie S; Yu Z; Liang Y; Gong T
Thorac Cancer; 2023 Aug; 14(24):2338-2349. PubMed ID: 37424279
[TBL] [Abstract][Full Text] [Related]
16. Quantitative CT evaluation after two cycles of induction chemotherapy to predict prognosis of patients with locally advanced oesophageal squamous cell carcinoma before undergoing definitive chemoradiotherapy/radiotherapy.
Yan S; Shi YJ; Liu C; Li XT; Zhao B; Wei YY; Shen L; Lu ZH; Sun YS
Eur Radiol; 2023 Jan; 33(1):380-390. PubMed ID: 35927466
[TBL] [Abstract][Full Text] [Related]
17. A machine learning approach using
Qi WX; Li S; Xiao J; Li H; Chen J; Zhao S
Front Immunol; 2024; 15():1351750. PubMed ID: 38352868
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma.
Yang W; Xing X; Yeung SJ; Wang S; Chen W; Bao Y; Wang F; Feng S; Peng F; Wang X; Chen S; He M; Zhang N; Wang H; Zeng B; Liu Z; Kidane B; Seder CW; Koyanagi K; Shargall Y; Luo H; Peng S; Cheng C
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35022193
[TBL] [Abstract][Full Text] [Related]
19. Contrast-enhanced CT-based radiomic analysis for determining the response to anti-programmed death-1 therapy in esophageal squamous cell carcinoma patients: A pilot study.
Yang Q; Huang H; Zhang G; Weng N; Ou Z; Sun M; Luo H; Zhou X; Gao Y; Wu X
Thorac Cancer; 2023 Nov; 14(33):3266-3274. PubMed ID: 37743537
[TBL] [Abstract][Full Text] [Related]
20. Tumor/normal esophagus ratio in (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for response and prognosis stratification after neoadjuvant chemotherapy for esophageal squamous cell carcinoma.
Izumi D; Yoshida N; Watanabe M; Shiraishi S; Ishimoto T; Kosumi K; Tokunaga R; Taki K; Higashi T; Harada K; Miyata T; Ida S; Imamura Y; Iwagami S; Baba Y; Sakamoto Y; Miyamoto Y; Yamashita Y; Baba H
J Gastroenterol; 2016 Aug; 51(8):788-95. PubMed ID: 26671045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
